Group 1 - The core point of the article is that Tianyu Co., Ltd. has received the CEP certificate from the European Medicines Agency for the active pharmaceutical ingredient of Telmisartan, which is used for treating primary hypertension and reducing cardiovascular risk [1] Group 2 - The announcement highlights the significance of the CEP certificate in ensuring the quality and compliance of the pharmaceutical product in the European market [1] - Telmisartan is specifically indicated for the treatment of primary hypertension and plays a role in lowering cardiovascular risk, indicating its importance in the healthcare sector [1]

Group 1 - The company Tianyu Co., Ltd. (300702.SZ) has received the Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines (EDQM) for the active pharmaceutical ingredient (API) of Telmisartan [1] - Telmisartan is used for the treatment of primary hypertension and for reducing cardiovascular risk [1]

证券代码：300702 证券简称：天宇股份 公告编号：2025-048 浙江天宇药业股份有限公司 关于公司原料药获得 CEP 证书的公告 本公司董事会及全体董事保证本公告内容不存在虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江天宇药业股份有限公司（以下简称"公司"）收到欧洲药品质量管理局 （以下简称"EDQM"）签发的关于替米沙坦工艺 II 原料药的欧洲药典适用性认 证证书（以下简称"CEP 证书"），现将相关情况公告如下： 一、药品基本情况 三、对公司的影响及风险提示 截至目前，本次公司替米沙坦工艺 II 原料药产品获得 CEP 证书，表明该原 料药符合欧洲药典的质量要求，显示欧洲市场对该原料药质量的认可和肯定，标 志着该原料药可以在欧洲市场及承认 CEP 证书的其他规范市场进行销售，为公 司进一步丰富产品及拓展国际市场带来积极的影响。由于该产品在国外市场销售 的时间、市场规模、后续拓展进度具有不确定性，药品出口业务容易受到国外市 场环境变化、汇率波动等因素影响，敬请广大投资者理性投资，注意防范投资风 药品名称：替米沙坦工艺 II 药品生产商/持有人：浙江天 ...

证券之星消息，8月11日化学制药板块较上一交易日上涨1.29%，天宇股份领涨。当日上证指数报收于 3647.55，上涨0.34%。深证成指报收于11291.43，上涨1.46%。化学制药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 300702 | 天宇股份 | 29.77 | 14.50% | 26.66万 | | 7.87亿 | | 300436 | 广生堂 | 132.81 | 11.70% | 16.11万 | | 20.37亿 | | 603538 | 美诺华 | 28.68 | 10.01% | 51.47万 | | 14.26 乙 | | 002826 | 易明医药 | 22.81 | 9.98% | 19.74万 | | 4.38亿 | | 300255 | 常山药业 | 44.46 | 8.52% | 55.73万 | | 24.31亿 | | 300233 | 金城医药 | 19.14 | 7.65% | 57.97万 | | 10.9 ...

金融界消息 截至2025年8月11日收盘，天宇股份（300702）报收于29.77元，上涨14.5%，换手率 12.62%，成交量26.66万手，成交金额7.87亿元。 通过天眼查大数据分析，浙江天宇药业股份有限公司共对外投资了22家企业，参与招投标项目20次，知 识产权方面有商标信息9条，专利信息75条，此外企业还拥有行政许可23个。 资金流向方面，今日主力资金净流入2339.14万元，占比成交额2.97%。其中，超大单净流入4081.19万 元、占成交额5.18%，大单净流出1742.05万元、占成交额2.21%，中单净流出流入467.86万元、占成交 额0.59%，小单净流出2807.00万元、占成交额3.57%。 来源：金融界 天宇股份最新一期业绩显示，截至2025一季报，公司营业总收入7.59亿元、同比增长10.13%，归属净利 润8618.35万元，同比增长112.71%，扣非净利润8233.83万元，同比增长56.79%，流动比率1.142、速动 比率0.466、资产负债率44.73%。 天眼查商业履历信息显示，浙江天宇药业股份有限公司，成立于2003年，位于台州市，是一家以从事医 药制造业为主 ...

Core Viewpoint - Zhejiang Tianyu Pharmaceutical Co., Ltd. has applied for a patent for a preparation method of Azilsartan Ester Potassium Salt, indicating innovation in pharmaceutical manufacturing [1] Company Overview - Zhejiang Tianyu Pharmaceutical Co., Ltd. was established in 2003 and is located in Taizhou, primarily engaged in the pharmaceutical manufacturing industry [1] - The company has a registered capital of 3,479.77159 million RMB [1] - The company has invested in 22 enterprises and participated in 20 bidding projects [1] - It holds 9 trademark information and 75 patent information, along with 23 administrative licenses [1] Patent Details - The patent application, published as CN120441565A, was filed on January 2025 [1] - The preparation method involves crystallization of Azilsartan Ester with Potassium Octanoate in an organic solvent at a temperature of 30-50°C, followed by aging treatment for at least 10 hours [1] - The method results in high yield, good purity, low impurity content, and significantly increased potassium ion content, demonstrating good stability [1] - The process conditions are milder, reducing energy consumption and eliminating the need for complex devices, enhancing operational practicality [1]

Group 1 - The stock price of Tianyu Co., Ltd. closed at 25.65 yuan on August 5, 2025, down by 0.15 yuan, a decrease of 0.58% from the previous trading day [1] - The trading volume on that day was 35,396 hands, with a transaction amount of 0.91 billion yuan, and a fluctuation of 2.17% [1] - Tianyu Co., Ltd. operates in the chemical pharmaceutical industry, focusing on the research, production, and sales of pharmaceutical intermediates, active pharmaceutical ingredients, and formulations [1] Group 2 - The company’s products cover multiple therapeutic areas, including antihypertensive, antihyperlipidemic, and antidiabetic treatments [1] - For the first half of 2025, the company expects a net profit attributable to shareholders of 1.3 billion to 1.8 billion yuan, representing a year-on-year growth of 144.29% to 238.25% [1] - On August 5, 2025, the net outflow of main funds was 5.96 million yuan, accounting for 0.11% of the circulating market value [1]

Core Viewpoint - Tianyu Co., Ltd. has received the European Pharmacopoeia Certificate of Suitability (CEP) for the active pharmaceutical ingredient Brivaracetam, which is used as an adjunctive treatment for partial seizures, particularly in patients who do not respond adequately to other antiepileptic drugs [1] Group 1 - Tianyu Co., Ltd. announced the receipt of the CEP certificate from the European Medicines Agency on August 1 [1] - Brivaracetam is specifically indicated for the adjunctive treatment of partial seizures [1] - The certification highlights the company's commitment to meeting European quality standards for its pharmaceutical products [1]

Group 1 - The company Tianyu Co., Ltd. (300702.SZ) has received the Certificate of Suitability for European Pharmacopoeia (CEP) issued by the European Medicines Agency for the active pharmaceutical ingredient Brivaracetam [1] - Brivaracetam is indicated for the adjunctive treatment of partial-onset seizures, particularly in patients who have inadequate response to other antiepileptic drugs [1]

证券代码：300702 证券简称：天宇股份 公告编号：2025-047 浙江天宇药业股份有限公司 关于公司原料药获得 CEP 证书的公告 生产地址：浙江省台州市临海市头门港经济开发区东海第五大道 15 号 证书编号：CEP 2025-089 - Rev 00 发证机构：欧洲药品质量管理局 本公司董事会及全体董事保证本公告内容不存在虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江天宇药业股份有限公司（以下简称"公司"）收到欧洲药品质量管理局 （以下简称"EDQM"）签发的关于布立西坦原料药的欧洲药典适用性认证证书 （以下简称"CEP 证书"），现将相关情况公告如下： 一、药品基本情况 药品名称：布立西坦 药品生产商/持有人：浙江天宇药业股份有限公司 化、汇率波动等因素影响，敬请广大投资者理性投资，注意防范投资风险。 特此公告。 浙江天宇药业股份有限公司董事会 二〇二五年八月二日 批准日期：2025 年 7 月 31 日 二、药品的其他相关情况 布立西坦适用于部分性癫痫发作的辅助治疗，尤其是对其他抗癫痫药物疗效 不足的患者。 公司于 2025 年 2 月向 EDQM ...